Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
View Patent ↗The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
1. A method of treating a patient with diffuse large cell lymphoma comprising administering anti-CD20 antibody and chemotherapy to the patient, wherein the patient is >60 years old, wherein the chemotherapy comprises CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone), and wherein the anti-CD20 antibody is administered to the patient in combination with stem cell transplantation regimen.
2. The method of claim 1 , wherein the antibody comprises a chimeric anti-CD20 antibody.
3. The method of claim 2 , wherein the antibody comprises rituximab.
4. The method of claim 1 , wherein the lymphoma is accompanied by bone marrow involvement.
5. A method of treating a patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) to the patient, in combination with stem cell transplantation, wherein the patient is >60 years old.